Hyderabad: City-based pharma player   Pharma on Wednesday announced that it has launched a generic version of multiple myeloma drug Pomalidomide in the Indian market. The company will market its generic Pomalidomide under the brand name Pomalid in India in 1 mg, 2 mg and 4 mg capsule strengths. Pomalidomide is a generic version of Celgene Incâ€™s Pomalyst brand. Natco said it has priced its Pomalid 1 mg, 2 mg, and 4 mg capsules at an MRP of Rs 5000, Rs 10,000, and Rs 20,000, respectively, for a monthly pack of 21 capsules. Pomalidomide is a Thalidomide analogue indicated in combination with dexamethasone for patients suffering from multiple myeloma (a type of blood cancer) who have received at least two prior therapies including Lenalidomide and a Proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy, the company said. tnn
